首页 >
法规速递
-
Document: Draft reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Revision 1-2026/4/24
2026-04-27查看详情 > -
Document: Agenda - Clinical trials information system information day webinar-2026/6/5
2026-06-08查看详情 > -
《药品召回管理办法》政策解读-2022/10/26
2022-11-14查看详情 > -
国家药监局药审中心关于发布《化药复方药物临床试验技术指导原则》的通告(2023年第15号)-2023/03/17
2023-03-17查看详情 > -
Draft Guidance: Demonstrating Substantial Evidence of Effectiveness Based on One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence-2023/9/18
2023-09-19查看详情 > -
Document: Information package for certificates of medicinal products issued by the European Medicines Agency-2025/1/6
2025-01-07查看详情 > -
Document: Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance-2025/2/10
2025-02-11查看详情 > -
Document: Seizing opportunities in a changing medicines landscape: The European medicines agencies network strategy 2028 (final)-2025/3/18
2025-03-19查看详情 > -
Document: European Medicines Agency’s data protection notice for EudraVigilance Human (EV)-2025/4/22
2025-04-23查看详情 > -
Document: Applicant / marketing authorisation holder change of contact person for product invented name / product number template-2025/6/2
2025-06-03查看详情 >
